Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial

Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial

Abstract Background Patients with non‐small‐cell lung cancer (NSCLC) and uncommon EGFR alterations typically have worse treatment outcomes than patients with classically EGFR‐mutated NSCLC. This study aimed to investigate the efficacy and safety of PD‐1 blockade with sintilimab plus anti‐angiogenic...

Full description

Bibliographic Details
Main Authors: Kaiyan Chen, Yanjun Xu, Zhiyu Huang, Xiaoqing Yu, Wei Hong, Hui Li, Xiaoling Xu, Hongyang Lu, Fajun Xie, Jun Chen, Youzu Xu, Yun Fan
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:Cancer Medicine
Subjects:
anlotinib
anti‐angiogenic
non‐small cell lung cancer (NSCLC)
PD‐1
sintilimab
uncommon EGFR mutations
Online Access:https://doi.org/10.1002/cam4.6548

Internet

https://doi.org/10.1002/cam4.6548

Similar Items